Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Public ClinicalTrials.gov record NCT01621802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when given as a second dose to children four to six years of age.
Study identification
- NCT ID
- NCT01621802
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 4,011 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 4 Years to 6 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2012 (Actual)
- Primary completion
- Jul 6, 2015 (Actual)
- Completion
- Nov 9, 2015 (Actual)
- Last update posted
- Nov 25, 2019
2012 – 2015
United States locations
- U.S. sites
- 50
- U.S. states
- 25
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35205 | — |
| GSK Investigational Site | Tucson | Arizona | 85704 | — |
| GSK Investigational Site | Tucson | Arizona | 85741 | — |
| GSK Investigational Site | Benton | Arkansas | 72019 | — |
| GSK Investigational Site | Fayetteville | Arkansas | 72703 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Anaheim | California | 92804 | — |
| GSK Investigational Site | Baldwin Park | California | 91706 | — |
| GSK Investigational Site | Daly City | California | 94015 | — |
| GSK Investigational Site | Fresno | California | 93726 | — |
| GSK Investigational Site | Hayward | California | 94545 | — |
| GSK Investigational Site | Oakland | California | 94611 | — |
| GSK Investigational Site | Pleasanton | California | 94588 | — |
| GSK Investigational Site | Sacramento | California | 95815 | — |
| GSK Investigational Site | Sacramento | California | 95823 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | Walnut Creek | California | 94596 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80922 | — |
| GSK Investigational Site | Altamonte Springs | Florida | 32701 | — |
| GSK Investigational Site | Marietta | Georgia | 30062 | — |
| GSK Investigational Site | Woodstock | Georgia | 30189 | — |
| GSK Investigational Site | Nampa | Idaho | 83686 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46256 | — |
| GSK Investigational Site | Augusta | Kansas | 67010 | — |
| GSK Investigational Site | Newton | Kansas | 67114 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Columbia | Maryland | 21045 | — |
| GSK Investigational Site | Fall River | Massachusetts | 02721 | — |
| GSK Investigational Site | The Bronx | New York | 10467 | — |
| GSK Investigational Site | Asheboro | North Carolina | 27203 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45245 | — |
| GSK Investigational Site | Cleveland | Ohio | 44121 | — |
| GSK Investigational Site | Dayton | Ohio | 45406 | — |
| GSK Investigational Site | Dayton | Ohio | 45414 | — |
| GSK Investigational Site | Gresham | Oregon | 97030 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16505 | — |
| GSK Investigational Site | Charleston | South Carolina | 29414 | — |
| GSK Investigational Site | Cheraw | South Carolina | 29520 | — |
| GSK Investigational Site | Rapid City | South Dakota | 57701 | — |
| GSK Investigational Site | Houston | Texas | 77055 | — |
| GSK Investigational Site | Tomball | Texas | 77375 | — |
| GSK Investigational Site | Provo | Utah | 84604 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84109 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
| GSK Investigational Site | St. George | Utah | 84790 | — |
| GSK Investigational Site | Burke | Virginia | 22015 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22902 | — |
| GSK Investigational Site | Huntington | West Virginia | 25701 | — |
| GSK Investigational Site | Monroe | Wisconsin | 53566 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01621802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2019 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01621802 live on ClinicalTrials.gov.